United States securities and exchange commission logo





                              February 8, 2024

       Brian S. John
       Chief Executive Officer
       Safety Shot, Inc.
       1061 E. Indiantown Rd., Ste. 110
       Jupiter, FL 33477

                                                        Re: Safety Shot, Inc.
                                                            Post-Effective
Amendment No. 6 on Form S-1
                                                            Filed February 5,
2024
                                                            File No. 333-258005

       Dear Brian S. John:

              We have conducted a limited review of the post-effective
amendment to your registration
       statement and have the following comments.

              Please respond to this letter by filing a post-effective
amendment and providing the
       requested information. If you do not believe a comment applies to your
facts and circumstances
       or do not believe an amendment is appropriate, please tell us why in
your response.

                After reviewing any amendment and the information you provide
in response to this
       letter, we may have additional comments.

       Post-Effective Amendment No. 6 to Form S-1

       Our Business
       Legal Proceedings, page 47

   1.                                                   We note your disclosure
concerning the written complaint sent by Bigger Capital Fund,
                                                        L.P. Please revise to
disclose the allegations or claims.
       General

   2.                                                   We note your response
to prior comment 3, which we reissue in part. With respect to
                                                        NoStingz, clarify if
the claims related to repelling jellyfish venom and protecting from sea
                                                        lice also fall within
the definition of cosmetics. With respect to SS-100, revise to further
                                                        clarify how SS-100
would be characterized as a drug in contrast to Safety Shot, which you
                                                        characterize as a
dietary/nutritional supplement. In addition, please disclose additional
                                                        information to clarify
the basis for your statement that SS-100 would qualify for Orphan
                                                        Drug Designation to
treat Acute Alcohol Poisoning. For example, clarify how Acute
 Brian S. John
Safety Shot, Inc.
February 8, 2024
Page 2
      Alcohol Poisoning meets the FDA   s definition of a Rare Disease. Please
also revise the
      Government Regulation section to clarify the process for seeking FDA
approval of a drug
      and for obtaining Orphan Drug Designation.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date.

       Please contact Juan Grana at 202-551-6034 or Margaret Sawicki at
202-551-7153 with
any other questions.



                                                           Sincerely,

FirstName LastNameBrian S. John                            Division of
Corporation Finance
                                                           Office of Industrial
Applications and
Comapany NameSafety Shot, Inc.
                                                           Services
February 8, 2024 Page 2
cc:       Arthur S. Marcus, Esq.
FirstName LastName